IBL Data Sheet

Code No. 10415

Anti-Human
CD20 (N) (4-6H:2C) Mouse IgG MoAb

Volume : 100 µg

Introduction : Rituximab used for treatment of lymphoma is an antibody drug of which target is pan-B cell marker, CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in a binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated.
This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to reserch of CD20.

Antigen : Synthetic peptide of the N-terminal part of human CD20 (CMQSGPKPLFRRMSS)

Source : Mouse-Mouse hybridoma (P3U1 × BALB/c mouse spleen cells)

Clone : 4-6H:2C **Subclass** : IgG3

Purification : Affinity purified with Protein A

Form : Lyophilized product from 1.0 mL of PBS containing 1 % BSA and 0.05 % NaN_3

How to use : 1.0 mL deionized water will be added to the product, then its concentration comes to 100 µg/mL

Stability : Lyophilized product, 5 years at 2 - 8 °C
: Solution, 2 years at –20 °C

Application : This antibody can be used for immunohistochemistry with formalin fixed paraffin embedded tissues after heat-induced antigen retrieval (boiling for 10 minutes or 40 minutes at 95 - 97°C, in 10 mM Tris-buffer/1 mM EDTA, pH 9.0). The recommended concentration is about 1 µg/mL, however, the concentration should be optimized by each laboratory.
: This antibody can be used for western blotting in concentration of about 1 µg/mL.

Reference : Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-Kuniyoshi R, Hatake K. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J. 2011 Apr;1(4):e15.

For research use only, not for use in diagnostic procedures.

Immuno-Biological Laboratories Co., Ltd. URL: http://www.ibl-japan.co.jp E-Mail: do-ibl@ibl-japan.co.jp

IBL Data Sheet

Code No. 10415

Anti-Human
CD20 (N) (4-6H:2C) Mouse IgG MoAb

Volume : 10 µg

Introduction : Rituximab used for treatment of lymphoma is an antibody drug of which target is pan-B cell marker, CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in a binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated.
This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to reserch of CD20.

Antigen : Synthetic peptide of the N-terminal part of human CD20 (CMQSGPKPLFRRMSS)

Source : Mouse-Mouse hybridoma (P3U1 × BALB/c mouse spleen cells)

Clone : 4-6H:2C **Subclass** : IgG3

Purification : Affinity purified with Protein A

Form : Lyophilized product from 0.1 mL of PBS containing 1 % BSA and 0.05 % NaN_3

How to use : 0.1 mL deionized water will be added to the product, then its concentration comes to 100 µg/mL

Stability : Lyophilized product, 5 years at 2 - 8 °C
: Solution, 2 years at –20 °C

Application : This antibody can be used for immunohistochemistry with formalin fixed paraffin embedded tissues after heat-induced antigen retrieval (boiling for 10 minutes or 40 minutes at 95 - 97°C, in 10 mM Tris-buffer/1 mM EDTA, pH 9.0). The recommended concentration is about 1 µg/mL, however, the concentration should be optimized by each laboratory.
: This antibody can be used for western blotting in concentration of about 1 µg/mL.

Reference : Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-Kuniyoshi R, Hatake K. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J. 2011 Apr;1(4):e15.

For research use only, not for use in diagnostic procedures.

Immuno-Biological Laboratories Co., Ltd. URL: http://www.ibl-japan.co.jp E-Mail: do-ibl@ibl-japan.co.jp